The clinical and economic impact of three-monthly long-acting formulation of paliperidone palmitate versus the one-monthly formulation in the treatment of schizophrenia in France: A cost-utility study-Reference-Cited by-同舟云学术

The clinical and economic impact of three-monthly long-acting formulation of paliperidone palmitate versus the one-monthly formulation in the treatment of schizophrenia in France: A cost-utility study

Published:2019-12 Issue:6 Volume:45 Page:459-467
ISSN:0013-7006
Container-title:L'Encéphale
language:en
Short-container-title:L'Encéphale

Author:

Arteaga Duarte C.H.,Fakra E.,Van Gils C.,Guillon P.

Publisher

Elsevier BV

Subject

Psychiatry and Mental health,Arts and Humanities (miscellaneous)

Reference41 articles.

1. Schizophrenia fact sheet. [Document online];World Health Organization,2016

2. Institut national de la santé et de la recherche medicale. Schizophrénie [Document online],2014

3. National Collaborating Centre for Mental Health England. Psychosis and schizophrenia in adults: treatment and management. NICE Clinical Guidelines no. 178,2014

4. The nature of relapse in schizophrenia;Emsley;BMC Psychiatry,2013

5. Early intervention in psychosis. The critical period hypothesis;Birchwood;Br J Psychiatry,1998

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia: A Critical Appraisal;Drug, Healthcare and Patient Safety;2023-09

2. Cost-utility analysis of using paliperidone palmitate in schizophrenia in China;Frontiers in Pharmacology;2023-08-03

3. Cost-effectiveness analysis of monthly, 3-monthly, and 6-monthly long-acting injectable and oral paliperidone in adults with schizophrenia;Journal of Managed Care & Specialty Pharmacy;2023-08

4. Effectiveness and Quality of Life with Paliperidone Palmitate 3-Monthly in Comparison with Other Long-Acting Drugs;Neuropsychiatric Disease and Treatment;2022-04

5. Second-generation long-acting injectable antipsychotics in clinical practice;Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova;2022